“Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus” (2023) SKIN The Journal of Cutaneous Medicine, 7(4), p. s226. doi:10.25251/skin.7.supp.226.